绿叶制药(02186.HK) 公布,集 团1类创新药LY03015已在内地完成II期临床试验的首例患者入组。LY03015为VMAT2(囊泡单胺转运蛋白2)抑制剂和Sigma-1受体激动剂,拟用于治疗迟发性运动障碍和亨廷顿病。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2025-01-15 16:25。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.